Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
Quorum Health said the move will allow it to save money through tax exemptions and provide its 11 hospitals with access to the 340B Drug Pricing Program. The health system is majority-owned by Goldentree Asset Management.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
The intrusion was caused by the compromised credentials of a Hartford HealthCare employee. Data stolen included full names, Medicaid ID numbers and patient treatment details.
Western medicine often functions more like a high-tech patient-processing machine than a high-touch people-healing mission. This can and must change, argue three distinguished healthcare thought leaders.
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June.
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
